Emerging linezolid-resistant, vancomycin resistant Enterococcus faecium from a patient of a haematological unit in Poland.
The oxazolidinone antimicrobial, linezolid, has been approved for the treatment of infections caused by various gram-positive bacteria, including vancomycin-resistant enterococci (VRE). This is the first report on isolation of a linezolid resistant, vancomycin-resistant Enterococcus faecium (LRVREF) strain in Poland, from a Haematological Unit patient in the Clinical Hospital in Gdańsk. PCR-RFLP analysis of rDNA and allele-specific PCR of the domain V region of the 23S ribosomal RNA gene demonstrated the presence of the G2576U mutation previously reported to be associated with linezolid resistance. Both assays detected heterozygous in this position.
Krawczyk
Beata
B
Department of Microbiology, Gdańsk University of Technology, ul G Narutowicza 11/12, 80-952 Gdańsk, Poland.
Samet
Alfred
A
Bronk
Marek
M
Hellmann
Andrzej
A
Kur
Józef
J
D000081:Acetamides / Q000494:pharmacology*; D000328:Adult; D024881:Drug Resistance, Bacterial; D016984:Enterococcus faecium / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D000069349:Linezolid; D008297:Male; D009154:Mutation; D023303:Oxazolidinones / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D020713:Vancomycin Resistance
D000081:Acetamides; D023303:Oxazolidinones; D000069349:Linezolid